Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/09/2021 06/10/2021 06/11/2021 06/14/2021 06/15/2021 Date
68.65(c) 69.29(c) 68.77(c) 68.15(c) 68.09 Last
8 434 161 8 678 419 6 928 016 5 319 472 6 453 471 Volume
+1.69% +0.93% -0.75% -0.90% -0.09% Change
More quotes
Financials (USD)
Sales 2021 24 680 M - -
Net income 2021 6 885 M - -
Net Debt 2021 21 984 M - -
P/E ratio 2021 12,9x
Yield 2021 4,12%
Sales 2022 23 833 M - -
Net income 2022 7 010 M - -
Net Debt 2022 17 208 M - -
P/E ratio 2022 12,5x
Yield 2022 4,33%
Capitalization 85 397 M 85 397 M -
EV / Sales 2021 4,35x
EV / Sales 2022 4,31x
Nbr of Employees 13 600
Free-Float 99,9%
More Financials
Company
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular... 
Sector
Biotechnology & Medical Research
Calendar
06/14
More about the company
Ratings of Gilead Sciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about GILEAD SCIENCES, INC.
02:53pUPDATE : Jounce Therapeutics to Get $25 Million From Gilead Sciences After FDA C..
MT
01:17pJounce Therapeutics Shares Rise 13% on IND Clearance for Cancer Treatment
DJ
10:03aJOUNCE THERAPEUTICSá : Set for $25 Million Milestone Payment from Gilead After I..
MT
08:02aGILEAD SCIENCESá : Jounce Therapeutics Achieves First Milestone in Exclusive Lic..
AQ
07:36aJounce Therapeutics Gets FDA Clearance for Cancer Treatment IND
DJ
06/14INSIDER TRENDS : Gilead Sciences Insider Converts Option/Derivative Security to ..
MT
06/14GILEAD SCIENCESá : University of Cambridge - Longer-term Data for Kite's Yescart..
AQ
06/14GILEAD SCIENCES'á : Lymphatic System Cancer Drug Shows 94% Response Rate in Foll..
MT
06/14GILEAD SCIENCES, INC. : Ex-dividend day for
FA
06/12GILEAD SCIENCESá : Longer-term Data for Kite's Yescarta« in Relapsed or Refracto..
BU
06/11STREET COLOR : Gilead Sciences' EMA States Causal Relationship Between Remdesivi..
MT
06/11GILEAD SCIENCESá : EMA Recommends Change To Product Information For Remdesivir T..
RE
06/11GILEAD SCIENCESá : U.S. Food and Drug Administration Approves New Formulation of..
AQ
06/11GILEAD SCIENCESá : Gets FDA Approval to Expand Hepatitis C Drug Indication to In..
MT
06/10GILEAD SCIENCESá : U.S. Food and Drug Administration Approves New Formulation of..
BU
More news
News in other languages on GILEAD SCIENCES, INC.
06/04Galapagos publiceert onderzoeksdata over filgotinib
06/03Covid, accordo Ue per 55.000 dosi trattamento sperimentale Roche-Regeneron
06/02DGAP-NEWS : MorphoSys übernimmt Constellation -2-
06/02DGAP-ADHOC : MorphoSys AG übernimmt Constellation -2-
05/18Galapagos start nieuwe studie naar filgotinib
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 75,15 $
Last Close Price 68,15 $
Spread / Highest target 46,7%
Spread / Average Target 10,3%
Spread / Lowest Target -12,0%
EPS Revisions
Managers and Directors
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.16.98%85 472
WUXI APPTEC CO., LTD.28.23%66 801
REGENERON PHARMACEUTICALS9.45%54 755
BIONTECH SE170.58%53 275
VERTEX PHARMACEUTICALS-17.58%50 427
BEIGENE, LTD.33.45%31 729